Transforming laboratory test results to improve clinical outcome predictions in HIV patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 5, 1998, Pages 442-449

  Perneger, Thomas V ^a   Yerly, Sabine ^b   Perrin, Luc ^b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

CD4+ cell counts; Clinical progression; HIV; HIV 1 RNA; Laboratory tests; Prediction models Mortality

Indexed keywords

BETA 2 MICROGLOBULIN; VIRUS RNA;

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0032522087     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199804150-00009     Document Type: Article

References (38)

1. Lagakos SW, Hoth DF. Surrogate markers in AIDS: Where are we? Where are we going? Ann Intern Med 1992;116:599-601.
2. Valentine FT, Jacobson MA. Immunological and virological markers in the evaluation of therapies for HIV infection. AIDS 1990;4(Suppl. 1):S201-7.
3. Machado SG, Gail MH, Ellenberg SS. On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1990;3:1065-73.
4. Deyton L. Importance of surrogate markers in evaluation of antiviral therapy for HIV infection. JAMA 1996;276:159-60.
5. Levy JA. Surrogate markers in AIDS research: is there truth in numbers? JAMA 1996;276:161-2.
6. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
7. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
8. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118:674-80.
9. Jacobson MA, De Gruttola V, Reddy M, et al. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. AIDS 1995;9:727-34.
10. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-8.
11. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
12. Galetto-Lacour A, Yerly S, Perneger TV, et al. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. J Infect Dis 1996;173:1388-93.
13. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
14. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologie and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
15. Nightingale SD, Jockusch JD, Haslund I, et al. Logarithmic relationship of the CD4 count to survival in patients with human immunodeficiency virus infection. Arch Intern Med 1993;153: 1313-8.
16. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
17. Jacobson MA, Bacchetti P, Kolokathis A, et al. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ 1991;302:73-8.
18. Lin DY, Fischl MA, Schoenfeld DA. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 1993;12:835-42.
19. Phillips AN, Sabin CA, Elford J, et al. Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection. BMJ 1994;309:309-13.
20. Saskela K, Stevens CE, Rubinstein P, et al. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 1995;123:641-8.
21. Welles SL, Jackson JB, Yen-Lieberman B, et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996;174:696-703.
22. Phillips AN, Eron JJ, Bartlett JA, et al. HIV-1 RNA levels and the development of clinical disease. AIDS 1996;10:859-65.
23. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-5.
24. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996;276:105-10.
25. Yerly S, Kaiser L, Mermillod B, et al. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995;9:159-63.
26. Lee TH, Sheppard HW, Reis M, et al. Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7:381-8.
27. Box GEP, Cox DR. An analysis of transformations (with discussion). J R Stat Soc B 1964;26:211-52.
28. Ledergerber B, von Overbeck J, Egger M, et al. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Präventivmed 1994;39:387-94.
29. + cell counts in HIV-infected patients. Arch Intern Med 1998;158:247-52.
30. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morbid Mortal Wkly Rep 1993;41(RR-17):1-19.
31. Collett D. Modelling survival data in medical research. London: Chapman & Hall, 1994.
32. Efron B, Tibshirani RJ. An introduction to the bootstrap. London: Chapman & Hall, 1993.
33. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Cont 1974;19:716-23.
34. Gupta P, Kingsley L, Armstrong J, et al. Enhanced expression of human immunodeficiency virus type 1 correlated with development of AIDS. Virology 1993;196:586-95.
35. Taylor JMG, Tan SJ, Detels R, Giorgi JV. Applications of a computer simulation model of the natural history of CD4T-cell number in HIV-infected individuals. AIDS 1991;5:159-67.
36. Yong FHL, Taylor JMG, Bryant JL, Chmiel JS, Gange SJ, Hoover D. Dependence of the hazard of AIDS on markers. AIDS 1997;11: 217-28.
37. Prentice R. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
38. Hughes MD, DeGruttola V, Welles SL. Evaluating surrogate markers. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10(Suppl. 2):S1-8.